Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Dec
20
2017
California Court of Appeal Affirms Judgment Finding No Duty to Defend Drug Manufacturer in Lawsuits Alleging Increased Opioid Usage Sheppard, Mullin, Richter & Hampton LLP
May
8
2021
FDA Proposes Risk-Based and Remote Inspection Strategies in New Report Sheppard, Mullin, Richter & Hampton LLP
Jul
11
2013
Farming Solar Rays: County Decision to Approve Industrial-Scale Solar on Williamson Act Lands OK'd Sheppard, Mullin, Richter & Hampton LLP
Oct
7
2013
California Passes Landmark Green Chemical Laws Sheppard, Mullin, Richter & Hampton LLP
Sep
20
2018
Federal Antitrust Regulators Approve Cigna’s Proposed Acquisition of Express Scripts Sheppard, Mullin, Richter & Hampton LLP
May
31
2014
Developer-Prepared Cost Comparisons Can Show Economic Infeasibility Under CEQA - California Environmental Quality Act Sheppard, Mullin, Richter & Hampton LLP
Aug
25
2022
Healthcare Reforms Under the IRA: Expanding Access to Care Sheppard, Mullin, Richter & Hampton LLP
Nov
3
2014
Agricultural Cooperative Antitrust Litigation Continues to Mushroom Sheppard, Mullin, Richter & Hampton LLP
Jan
5
2015
New FDA Draft Guidance on REMS and Bioequivalence Studies: Does New Procedure Secure ANDA Applicants The Right to Obtain Samples? Sheppard, Mullin, Richter & Hampton LLP
Mar
20
2023
FDA Draft Guidance Signifies Acceptance of the Term “Milk” to Describe Plant-Based Alternatives Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2020
FDA Grants COVID-19 Diagnostic Emergency Use Authorizations, And Other Recent FDA Actions to Address COVID-19 Sheppard, Mullin, Richter & Hampton LLP
May
12
2020
“Happy Cows” False Labeling Theory is Just “Half Baked”: Court Dismisses False Advertising Claims Against Ben & Jerry’s Sheppard, Mullin, Richter & Hampton LLP
Apr
3
2024
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA Sheppard, Mullin, Richter & Hampton LLP
May
7
2024
Cannabis Operator Challenges California State Statute and Regulations Requiring Labor Peace Agreements Sheppard, Mullin, Richter & Hampton LLP
Jul
2
2010
US Patent Office Expands Green Technology Accelerated Examination Program - More categories of invention are now eligible for expedited processing Sheppard, Mullin, Richter & Hampton LLP
Feb
8
2011
The Tax Relief, Unemployment Insurance Reauthorization and Job Creation Act of 2010 and its effect on the Energy Sector Sheppard, Mullin, Richter & Hampton LLP
Dec
11
2017
Texas Telemedicine Saga Finally Over? The Texas Medical Board Substantially Revises Telemedicine Regulations Sheppard, Mullin, Richter & Hampton LLP
Dec
19
2011
Taking a Cue From Brazil's Sustainable Development Practices Past and Present Sheppard, Mullin, Richter & Hampton LLP
Feb
17
2022
FDA Boosts Protein Preemption Defense Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2013
New “Potentially Feasible” Alternative Does Not Trigger Draft Environmental Impact Report (EIR) Recirculation Unless Considered “Significant New Information”; No Findings Needed to Reject Alternative As Infeasible Sheppard, Mullin, Richter & Hampton LLP
Jun
29
2022
California District Court Finds that EKRA Applies to Compensation Methodologies for Labs’ Employed Marketers Who Market to Physicians Sheppard, Mullin, Richter & Hampton LLP
Jul
6
2022
California Governor Signs into Law Cannabis Tax Relief Bill Sheppard, Mullin, Richter & Hampton LLP
Mar
21
2019
Federal Circuit Weighs in on Patent Subject-Matter Eligibility of Dietary Supplements Sheppard, Mullin, Richter & Hampton LLP
Oct
27
2022
FDA Proposes Updated Rule for “Healthy” Foods Sheppard, Mullin, Richter & Hampton LLP
Feb
12
2015
Interface without Regulation – FDA Deregulates MDDS and Related Technologies Sheppard, Mullin, Richter & Hampton LLP
Jun
10
2015
NDRC Issued Opinions and Notice on Drug Price Reform: National Development and Reform Commission Sheppard, Mullin, Richter & Hampton LLP
Sep
7
2023
Context is Key: FDA Sends a Strong Message About Efficacy Claims Sheppard, Mullin, Richter & Hampton LLP
Sep
28
2023
A Second Chance to Win Your Government Healthcare Contract Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins